Simon M
Senior Member (Voting Rights)
They have a plan
Just about every other "potential biomarker" has faded away . What is encouraging about this one is both the dramatic difference between patients and controls, and the fact that they have a clear plan to develop it.
First, they aim to test the performance of the assay on other similar condition diseases (I had missed this the first time I read the paper). (I am guessing the diseases don't include depression, though for me it is important to substantiate the claims this is a clear biomedical problem).
Second, they have said elsewhere that they are aiming to replicate the results on a larger cohort of patients.
In addition they plan further experiments to understand the specific biological mechanisms underlying the impedance differences.
They are also working on adapting the technology to a platform for preclinical testing of drugs/therapies on cells from ME/CFS patients "leading towards development of a portable, hand-held, and easy-to-use platform that can be operated by researchers and clinicians at any skill level." I think the replication and use of sick controls is importance to do first, to validate the test, before moving to drug development.
I am not sure if this phrasing includes an easy-to-use diagnostic, but elsewhere in the paper they made clear they are trying to modify the technology so that the test could be done in a Dr's office.
Plus, Open medicine Foundation have the funds to see this work through and I imagine publication of this paper will help secure further funding.
This work should progress through to a result, hopefully an effective diagnostic and ideally something that will also help to reveal underlying biological mechanisms of the disease.
Just about every other "potential biomarker" has faded away . What is encouraging about this one is both the dramatic difference between patients and controls, and the fact that they have a clear plan to develop it.
First, they aim to test the performance of the assay on other similar condition diseases (I had missed this the first time I read the paper). (I am guessing the diseases don't include depression, though for me it is important to substantiate the claims this is a clear biomedical problem).
Second, they have said elsewhere that they are aiming to replicate the results on a larger cohort of patients.
In addition they plan further experiments to understand the specific biological mechanisms underlying the impedance differences.
They are also working on adapting the technology to a platform for preclinical testing of drugs/therapies on cells from ME/CFS patients "leading towards development of a portable, hand-held, and easy-to-use platform that can be operated by researchers and clinicians at any skill level." I think the replication and use of sick controls is importance to do first, to validate the test, before moving to drug development.
I am not sure if this phrasing includes an easy-to-use diagnostic, but elsewhere in the paper they made clear they are trying to modify the technology so that the test could be done in a Dr's office.
Plus, Open medicine Foundation have the funds to see this work through and I imagine publication of this paper will help secure further funding.
This work should progress through to a result, hopefully an effective diagnostic and ideally something that will also help to reveal underlying biological mechanisms of the disease.
Last edited: